Stock listing
A2QNWS Stock Price, News, Filings & Events — Pharvaris N.v.
Selected listing: A2QNWS · LS · EUR · DE
This page tracks Pharvaris N.v.'s A2QNWS:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2QNWS:LS. A2QNWS:LS is the stock-level entry point for investors researching Pharvaris N.v., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A2QNWS:LS
- Asset type
- Stock
- Market cap
- $2.66B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Pharvaris N.v. A2QNWS:LS stock context
This page tracks Pharvaris N.v.'s A2QNWS:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2QNWS:LS. A2QNWS:LS is the stock-level entry point for investors researching Pharvaris N.v., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Pharvaris N.v.
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
September 8, 2026
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
September 3, 2026
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated T...
July 22, 2026
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
July 6, 2026
Research Pharvaris N.v.
Pharvaris N.v. investor report
Review AI stock analysis and investor report context for A2QNWS:LS.
Pharvaris N.v. company profile
View the public company page for Pharvaris N.v. on 6ix.
Pharvaris N.v. news
Read company news and market updates connected to Pharvaris N.v..
Pharvaris N.v. investor events
Find investor webinars, events, and replay context for Pharvaris N.v..
Alternate listings
PHVS:NASDAQ
US · USD
Alternate listing for Pharvaris N.v.; the primary context on this page is A2QNWS:LS.
9EN:GETTEX
DE · EUR
Alternate listing for Pharvaris N.v.; the primary context on this page is A2QNWS:LS.
A2QNWS:LSX
DE · EUR
Alternate listing for Pharvaris N.v.; the primary context on this page is A2QNWS:LS.
9EN:TRADEGATE
DE · EUR
Alternate listing for Pharvaris N.v.; the primary context on this page is A2QNWS:LS.
PHVS:BOATS
US · USD
Alternate listing for Pharvaris N.v.; the primary context on this page is A2QNWS:LS.
9EN:FWB
DE · EUR
Alternate listing for Pharvaris N.v.; the primary context on this page is A2QNWS:LS.
9EN:DUS
DE · EUR
Alternate listing for Pharvaris N.v.; the primary context on this page is A2QNWS:LS.
9EN:MUN
DE · EUR
Alternate listing for Pharvaris N.v.; the primary context on this page is A2QNWS:LS.
9EN:SWB
DE · EUR
Alternate listing for Pharvaris N.v.; the primary context on this page is A2QNWS:LS.